Randomized Phase II Study of BEZ235 or Everolimus in Advanced Pancreatic Neuroendocrine Tumors

Trial Profile

Randomized Phase II Study of BEZ235 or Everolimus in Advanced Pancreatic Neuroendocrine Tumors

Discontinued
Phase of Trial: Phase II

Latest Information Update: 11 Apr 2016

At a glance

  • Drugs Dactolisib (Primary) ; Everolimus
  • Indications Neuroendocrine tumours; Pancreatic cancer
  • Focus Therapeutic Use
  • Acronyms MACS1938
  • Sponsors Novartis
  • Most Recent Events

    • 09 Mar 2016 Status changed from completed to discontinued based on an interim analysis as BEZ235 did not demonstrate a progression free survival advantage to everolimus treatment, according to ClinicalTrials.gov record.
    • 02 Jun 2015 Results presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
    • 23 Nov 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top